Protocol Ledger

NCT06682195 · Phase II · RECRUITING

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Interventional Phase II clinical trial protocol NCT06682195 sponsored by First Affiliated Hospital of Zhejiang University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-09 Enrollment: 35 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06682195
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)35 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06682195
Protocol FieldVerified Registry Value
NCT IdentifierNCT06682195
Consolidated Lead SponsorFirst Affiliated Hospital of Zhejiang University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment35 participants (ESTIMATED)
Registered Start Date2024-10-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06682195
Hospital Research SiteLocationSite Profile
Zhejiang Cancer HospitalHangzhou, ChinaOpen Hospital Dossier ->
Harbin Medical University Cancer HospitalHarbin, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI